Nasdaq
$18.53▼ 0.22%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $75.0MShares out 4.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
41- 10.15Overnight26.10.15 10:394Ownership#●●●
Cue Biopharma, Inc.
Insider Ray Sumita reported a change in beneficial ownership of Cue Biopharma, Inc. securities as of October 12, 2026. This filing serves as a standard disclosure of executive equity changes and does not involve material corporate events such as financing or delisting.…more
$18.53-0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Overnight26.10.15 10:384Ownership
Cue Biopharma, Inc.
Insider Michael Vincent Meluzio of Cue Biopharma, Inc. reported a change in his beneficial ownership of securities as of October 12, 2026. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more
$18.53-0.22%vs prev closeView filingShare - 10.15Overnight26.10.15 10:374Ownership
Cue Biopharma, Inc.
Insider Lin Shao-Lee reported a change in beneficial ownership of Cue Biopharma, Inc. securities as of October 12, 2026. This filing provides the details of the insider transaction in accordance with Form 4 requirements.…more
$18.53-0.22%vs prev closeView filingShare
40 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.21Regular26.09.21 23:45#●●●#●●●
Cue Biopharma Shares Tumble Despite Positive Phase 2 Results
Cue Biopharma announced that its CUE-221 drug candidate met primary and secondary endpoints in a Phase 2 trial for chronic spontaneous urticaria. Despite the positive clinical data, the company's stock price fell significantly by over 28% during Monday's trading session.…more
$18.53-0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.21Overnight26.09.21 15:32
●●●●●●●● ●●●●● ●●●●●●
Cue Biopharma's CUE-221 met primary and secondary endpoints in a Phase 2 study, showing superior symptom resolution compared to omalizumab. The drug demonstrated a favorable safety profile and a distinct mechanism of action, highlighting its potential in treating chronic spontaneous urticaria.…more
$18.53-0.22%vs prev closeShareBenzinga - 9.20Closed26.09.20 19:00
●●●●●●●● ●●●●● ●●●●●●
Cue Biopharma announced that its CUE-221 candidate met primary and key secondary endpoints in a Phase 2 study for chronic spontaneous urticaria. The company plans to advance to a Phase 2b/3 registration study, though further clinical validation remains necessary.…more
$18.53-0.22%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report